Dorien J M Peters Selected Research

Autosomal Dominant Polycystic Kidney (ADPKD)

1/2022	Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
1/2022	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.
1/2022	Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients.
10/2020	Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease.
1/2020	The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo.
1/2020	Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles.
1/2020	Reducing YAP expression in Pkd1 mutant mice does not improve the cystic phenotype.
1/2020	Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective.
12/2019	Characterisation of transcription factor profiles in polycystic kidney disease (PKD): identification and validation of STAT3 and RUNX1 in the injury/repair response and PKD progression.
9/2019	Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dorien J M Peters Research Topics

Disease

39	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2022 - 01/2002
23	Cysts 01/2020 - 09/2005
18	Polycystic Kidney Diseases (Polycystic Kidney Disease) 01/2020 - 09/2005
11	Disease Progression 01/2022 - 03/2014
3	Cystic Kidney Diseases (Cystic Kidney Disease) 12/2019 - 01/2017
3	Polycystic liver disease 01/2019 - 03/2014
2	Ciliopathies 01/2022 - 01/2018
2	Inflammation (Inflammations) 01/2020 - 01/2020
2	Infections 11/2018 - 01/2017
2	Renal Insufficiency (Renal Failure) 03/2015 - 10/2009
2	Rubinstein-Taybi Syndrome (Syndrome, Rubinstein-Taybi) 04/2005 - 02/2003
1	Obesity 01/2022
1	Polyuria 01/2022
1	Kidney Diseases (Kidney Disease) 01/2019
1	Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I) 12/2018
1	Chronic Renal Insufficiency 03/2018
1	Hydrocephalus (Hydrocephaly) 01/2018
1	Hypoxia (Hypoxemia) 12/2016
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 04/2016
1	Stroke (Strokes) 04/2016
1	CADASIL 04/2016
1	Cerebral Small Vessel Diseases 04/2016

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2002
7	Pharmaceutical PreparationsIBA 01/2022 - 01/2017
7	Biomarkers (Surrogate Marker)IBA 01/2019 - 11/2010
5	lanreotide (Somatuline)FDA Link 01/2019 - 03/2014
4	Tolvaptan FDA Link 01/2022 - 01/2019
3	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2022 - 01/2016
3	TOR Serine-Threonine KinasesIBA 10/2019 - 05/2011
3	CalciumIBA 12/2018 - 01/2016
3	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 11/2018 - 03/2014
2	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 09/2019
2	Antisense OligonucleotidesIBA 01/2020 - 04/2016
2	Adenosine Triphosphate (ATP)IBA 01/2020 - 12/2016
2	Transcription Factors (Transcription Factor)IBA 12/2019 - 09/2005
2	Urea (Carbamide)FDA LinkGeneric 09/2019 - 06/2013
2	AlbuminsIBA 01/2019 - 11/2010
2	Biological ProductsIBA 12/2018 - 12/2016
2	Sirolimus (Rapamycin)FDA Link 12/2018 - 05/2012
2	Epidermal Growth Factor (EGF)IBA 01/2017 - 04/2016
2	ChloridesIBA 12/2016 - 01/2016
2	TRPP Cation ChannelsIBA 10/2011 - 10/2009
2	Tamoxifen FDA LinkGeneric 07/2009 - 12/2007
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 09/2005 - 06/2004
2	CREB-Binding ProteinIBA 04/2005 - 02/2003
1	Inositol (Myoinositol)IBA 01/2022
1	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2022
1	Citric Acid (Citrate)FDA LinkGeneric 01/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022
1	SaltsIBA 10/2020
1	Dinoprostone (PGE2)FDA Link 01/2020
1	TriterpenesIBA 01/2020
1	Adenosine Monophosphate (AMP)IBA 01/2020
1	gamma-Linolenic AcidIBA 01/2020
1	Pioglitazone (Actos)FDA Link 01/2020
1	Rosiglitazone (Avandia)FDA Link 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	celastrolIBA 01/2020
1	CytokinesIBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Meclofenamic Acid (Meclofenamate)FDA LinkGeneric 01/2020
1	birinapantIBA 01/2020
1	ChromatinIBA 12/2019
1	Folic Acid (Vitamin M)FDA LinkGeneric 10/2019
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 10/2019
1	dactolisibIBA 10/2019
1	PlatinumIBA 10/2019
1	AMP-Activated Protein KinasesIBA 09/2019
1	CanagliflozinIBA 09/2019
1	NitrogenIBA 09/2019
1	salicylsalicylic acid (salsalate)IBA 09/2019
1	Fatty Acid-Binding ProteinsIBA 01/2019
1	Lipocalin-2IBA 01/2019
1	Immunoglobulin G (IgG)IBA 01/2019
1	mozavaptanIBA 01/2019
1	Antihypertensive Agents (Antihypertensives)IBA 01/2019
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2018
1	Prolyl-Hydroxylase InhibitorsIBA 11/2018
1	Iothalamic Acid (Iotalamic Acid)FDA Link 03/2018
1	ATPases Associated with Diverse Cellular ActivitiesIBA 01/2018
1	ElectrolytesIBA 01/2018
1	Aurora KinasesIBA 01/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	ColforsinIBA 01/2017
1	Growth Hormone (Somatotropin)IBA 01/2017
1	Activins (Activin)IBA 12/2016
1	LigandsIBA 12/2016
1	Activin Receptors (Activin Receptor)IBA 12/2016
1	Complement C3 (C3 Complement)IBA 10/2016
1	PlakinsIBA 10/2016
1	Complement System Proteins (Complement)IBA 10/2016
1	envoplakinIBA 10/2016
1	Notch3 ReceptorIBA 04/2016
1	Cysteine (L-Cysteine)FDA Link 04/2016
1	Low Density Lipoprotein Receptor-Related Protein-5IBA 02/2016

Therapy/Procedure

10	Therapeutics 01/2022 - 05/2011
2	Renal Replacement Therapy (Therapies, Renal Replacement) 11/2018 - 07/2009
1	Sodium-Restricted Diet (Diet, Sodium Restricted) 01/2019
1	Glycemic Control 01/2016